Section 1 of 8What is MK777?
What is MK777?
Acetamoren is a small organic molecule commercially called MK777 or MK-777. LGC/TRC lists it under CAS 950841-87-9; its structure matches the PubChem entry named N-Acetyl Ibutamorelin. The commercial name does not establish the contents of an individual product. This article concerns that identified structure, not every product carrying the name. C01 (opens in a new tab)
Section 2 of 8How does it differ from MK677?
How does it differ from MK677?
Compared with ibutamoren (MK-677), acetamoren has an acetyl group attached to the nitrogen of a free amino group: an amine becomes an amide. This is a covalent structural change, not merely a different salt. The structures support the description N-acetylated ibutamoren; they do not establish a better clinical effect. C02 (opens in a new tab)
Section 3 of 8What does the patent show?
What does the patent show?
A structure matching acetamoren appears as compound 126 in Table 1 of patent application US20050187237A1, published in 2005. It is assigned category B, defined as agonist activity with EC₅₀ below 100 nM in a cell-based assay. An agonist activates a receptor; here the target is the ghrelin receptor. This is patent-reported preclinical evidence, not a human trial or independent replication. The table does not establish superiority over ibutamoren. C03 (opens in a new tab)
Section 4 of 8What might the structural change do?
What might the structural change do?
Structural interpretation, not a measured effect: changing this amine into an amide makes the nitrogen much less able to acquire a positive charge. It also changes local size and hydrogen-bonding properties. This could alter receptor contacts, membrane passage or metabolism, but the structure alone does not determine the direction or magnitude. Weaker binding, better absorption and slower breakdown remain hypotheses, not established properties of acetamoren. C04 (opens in a new tab)
Section 5 of 8Are there human studies?
Are there human studies?
The documented searches on 2026-09-14 found no PubMed records under acetamoren or MK777/MK-777 and no registered trials under the checked names in ClinicalTrials.gov. Searches also covered N-Acetyl Ibutamorelin and selected identifiers. This is a dated search result, not proof that no study exists under another designation. The older patent finding must therefore be distinguished from the absence of identified clinical evidence. C05 (opens in a new tab)
Section 6 of 8What about blood glucose and hunger?
What about blood glucose and hunger?
In a randomized trial of ibutamoren in older adults, growth hormone and IGF-1 increased, fasting glucose rose and insulin sensitivity decreased; strength and function did not improve. Those findings concern ibutamoren, not acetamoren. They provide context for the comparison, not a measurement of acetamoren risk. Less hunger would not by itself demonstrate better glucose control, and no such comparative benefit was established in the reviewed material. C06 (opens in a new tab)
Section 7 of 8What is known about dosing?
What is known about dosing?
No supported human regimen for acetamoren was identified in the reviewed material. Receptor activity in a cell assay cannot be converted into an oral dose. Nor does the structural change justify using the same milligram amount as ibutamoren, increasing it to compensate for hypothetical weaker binding, or assuming a longer dosing interval. Human absorption, metabolism, half-life and tolerability remain unresolved. C07 (opens in a new tab)
Section 8 of 8Is it an improved replacement?
Is it an improved replacement?
The identified chemical structure and patent-reported activity warrant describing acetamoren as a distinct research subject. They do not establish a safer or more effective replacement for MK677. A chemical identity record is not a medicine approval. Product contents, clinical benefit and safety are separate questions; conclusions about them require their own evidence. C08 (opens in a new tab)